Phase 1 Dose Escalation, Multi-tumor Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered MAGE-A4ᶜ¹º³²T in HLA-A2+ Subjects With MAGE-A4 Positive Tumors

Trial Profile

Phase 1 Dose Escalation, Multi-tumor Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered MAGE-A4ᶜ¹º³²T in HLA-A2+ Subjects With MAGE-A4 Positive Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Nov 2017

At a glance

  • Drugs Melanoma-associated-antigen-A4-specific-T-cells-Adaptimmune (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Adenocarcinoma; Bladder cancer; Gastric cancer; Head and neck cancer; Large cell carcinoma; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Adaptimmune
  • Most Recent Events

    • 03 Nov 2017 According to an Adaptimmune media release, the study design of this trial will be presented at the 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting.
    • 10 May 2017 According to an Adaptimmune media release, the comcompany expects initial data from this study in 2017 and 2018.
    • 03 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top